Abstract
BackgroundThe aim was to study the glycaemic control of type 2 diabetic patients, and to identify factors associated with unacceptable glycaemic control (defined as HbA1c >8.0%).MethodsAnalysis of data collected in a cross-sectional survey of type 2 diabetic patients in eight SingHealth Polyclinics in January 2009. HbA1c value was measured on the day of the survey, while information on patient and diabetic characteristics was obtained through a questionnaire. Odds ratio of having unacceptable glycaemic control was estimated for selected variables using multiple logistic regression models.ResultsA total of 688 patients were included in the analysis. The mean (± standard deviation) and median (range) HbA1c levels were 7.6% (± 1.35) and 7.3% (5.0% to 14.0%), respectively. 25.4% of the patients had an unacceptable HbA1c level of >8.0% and the odds of this were higher (p < 0.05) in patients with the following characteristics: younger age, longer diabetes duration, presence of insulin treatment, and poorer compliance to medication.ConclusionYounger adult patients were found to have poorer glycaemic control, and hence targeted educational and behaviour modification programmes would be required to effectively manage this group of patients.
Highlights
The aim was to study the glycaemic control of type 2 diabetic patients, and to identify factors associated with unacceptable glycaemic control
Each 1% reduction in updated mean HbA1c has been shown to be associated with reduction in risk of 21% for deaths related to diabetes, 14% for myocardial infarction, and 37% for microvascular complications [5]
The aim of our study was to 1) investigate the prevalence of suboptimal glycaemic control and 2) identify factors associated with unacceptable glycaemic control in type 2 diabetes mellitus patients treated and followed up in SingHealth polyclinics
Summary
The aim was to study the glycaemic control of type 2 diabetic patients, and to identify factors associated with unacceptable glycaemic control (defined as HbA1c >8.0%). Type 2 diabetes mellitus causes significant mortality and morbidity [3] due to its long-term micro-vascular and macro-vascular complications, and these adverse outcomes are associated with poorer glycaemic control [4]. There is increasing recognition that intensive (versus conventional) glucose lowering treatment has limited benefits on all-cause mortality and deaths from cardiovascular causes, and the harm associated with severe hypoglycemia might counter balance the potential benefit of intensive glucose lowering treatment [8]. This suggests that glucose-lowering regimens should be tailored to the individual patient
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
